ArticleWorld journal of gastroenterology2014
Effects of baicalin in CD4 + CD29 + T cell subsets of ulcerative colitis patients.
Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Potential Therapeutic Effects of Natural Plant Compounds in Kidney Disease.Molecules (Basel, Switzerland) · 2021Pooled it
- Immunomodulatory Effects of Flavonoids in Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2026Review
- Identification and quantification of putative active constituents of huangqin decoction for ulcerative colitis treatment through the integration of chemical profiling, network pharmacology, and bioinformatics.Frontiers in chemistry · 2026Article
- Article
- Harnessing the Anti-Inflammatory Properties of Polyphenols in the Treatment of Inflammatory Bowel Disease.International journal of biological sciences · 2024Review
- The Antioxidant Properties ofAntioxidants (Basel, Switzerland) · 2023Article
- Baicalin Weakens the Porcine ExPEC-Induced Inflammatory Response in 3D4/21 Cells by Inhibiting the Expression of NF-Microorganisms · 2023Article
- The Pharmacological Efficacy of Baicalin in Inflammatory Diseases.International journal of molecular sciences · 2023Review
- Identification of three cultivated varieties of Scutellaria baicalensis using the complete chloroplast genome as a super-barcode.Scientific reports · 2023Article
- Chinese herbal medicines for treating ulcerative colitis via regulating gut microbiota-intestinal immunity axis.Chinese herbal medicines · 2023Review
- Repairing the intestinal mucosal barrier of traditional Chinese medicine for ulcerative colitis: a review.Frontiers in pharmacology · 2023Review
- Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review.World journal of gastroenterology · 2022Review
- Baicalin relievesMolecular medicine reports · 2021Article
- Herbal pair Huangqin-Baishao: mechanisms underlying inflammatory bowel disease by combined system pharmacology and cell experiment approach.BMC complementary medicine and therapies · 2020Article
- Baicalin Is Curative Against Rotavirus Damp Heat Diarrhea by Tuning Colonic Mucosal Barrier and Lung Immune Function.Digestive diseases and sciences · 2020Article
- Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.Chinese medicine · 2020Review
- Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Review
- Review
- Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23/IL-17 axis.American journal of translational research · 2018Article
- Baicalin Alleviates Lipopolysaccharide-Induced Liver Inflammation in Chicken by Suppressing TLR4-Mediated NF-κB Pathway.Frontiers in pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the role of baicalin in ulcerative colitis (UC) with regard to the CD4(+)CD29(+) T helper cell, its surface markers and serum inflammatory cytokines.
methodsFlow cytometry was used to detect the percentage of CD4(+)CD29(+) cells in patients with UC. Real time polymerase chain reaction was used to detect expression of GATA-3, forkhead box P3, T-box expressed in T cells (T-bet), and retinoic acid-related orphan nuclear hormone receptor C (RORC). Western blotting was used to analyze expression of nuclear factor-κB (NF-κB) p65, phosphorylation of NF-κB (p-NF-κB) p65, STAT4, p-STAT4, STAT6 and p-STAT6. The concentrations of interferon-γ (IFN-γ), interleukin (IL)-4, IL-5, IL-6, IL-10 and TGF-β in serum were determined by ELISA assay.
resultsThe percentages of CD4(+)CD29(+) T cells were lower in treatment with 40 and 20 μmol/L baicalin than in the treatment of no baicalin. Treatment with 40 or 20 μmol/L baicalin significantly upregulated expression of IL-4, TGF-β1 and IL-10, increased p-STAT6/STAT6 ratio, but downregulated expression of IFN-γ, IL-5, IL-6, RORC, Foxp3 and T-bet, and decreased ratios of T-bet/GATA-3, p-STAT4/STAT4 and p-NF-κB/NF-κB compared to the treatment of no baicalin.
conclusionThe results indicate that baicalin regulates immune balance and relieves the ulcerative colitis-induced inflammation reaction by promoting proliferation of CD4(+)CD29(+) cells and modulating immunosuppressive pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.